How to buy Exscientia stock (Exscientia Ltd)

Exscientia is a biotechnology business based in the US. Exscientia shares (EXAI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.84 – the same closing value as a week prior. Exscientia employs 483 staff and has a trailing 12-month revenue of around $17.1 million.

Our top picks for where to buy Exscientia Ltd ADR stock

Buy Exscientia stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Exscientia stock price (NASDAQ: EXAI)

Use our graph to track the performance of EXAI stocks over time.

Exscientia shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$4.84
52-week range	$3.80 - $7.91
50-day moving average more info button	$5.04
200-day moving average more info button	$5.26
Wall St. target price	$4.35
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.51

Is it a good time to buy Exscientia stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Exscientia price performance over time

Historical closes compared with the close of $4.84 from 2024-11-20

1 week (2024-12-14)	N/A
1 month (2024-11-21)	N/A
3 months (2024-09-25)	-5.84%
6 months (2024-06-25)	-8.51%

1 year (2023-12-22)	-26.33%
2 years (2022-12-23)	10.76%
3 years (2021-12-23)	19.54
5 years (2019-12-21)	N/A

Exscientia financials

Revenue TTM	$17.1 million
Gross profit TTM	$10.2 million
Return on assets TTM	-21.22%
Return on equity TTM	-46.43%
Profit margin	0%
Book value	$1.95
Market Capitalization more info button	$633.2 million

TTM: trailing 12 months

Exscientia share dividends

We're not expecting Exscientia to pay a dividend over the next 12 months.

You may also wish to consider:

Exscientia share price volatility

Over the last 12 months, Exscientia's shares have ranged in value from as little as $3.8 up to $7.91. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exscientia's is 0.835. This would suggest that Exscientia's shares are less volatile than average (for this exchange).

To put Exscientia's beta into context you can compare it against those of similar companies.

• Schrodinger (SDGR.US): 1.501
• Certara (CERT.US): 1.511
• Recursion Pharmaceuticals (RXRX.US): 0.802

Exscientia overview

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom. .

Frequently asked questions

null
What percentage of Exscientia is owned by insiders or institutions?
Currently 25.903% of Exscientia shares are held by insiders and 20.805% by institutions. How many people work for Exscientia?
Latest data suggests 483 work at Exscientia. When does the fiscal year end for Exscientia?
Exscientia's fiscal year ends in December. Where is Exscientia based?
Exscientia's address is: The SchrOedinger Building, Oxford, United Kingdom, OX4 4GE What is Exscientia's ISIN number?
Exscientia's international securities identification number is: US30223G1022